在A4研究中,研究跨种族/民族,性别和Aβ状态群体的临床前阿尔茨海默症认知复合和认知功能指数的因子结构
M Ruthirakuhan1, M Wood Alexander, H Cogo-Moreira
1Jennifer Rabin, PhD, C.Psych, Sunnybrook Health Sciences Centre, Room M6-178, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada, Phone: 416-480-6100 ext. 83737,
The journal of prevention of Alzheimer's disease
|January 17, 2024
概括
像临床前阿尔茨海默氏症认知复合物 (PACC) 和认知功能指数这样的认知评估在各种种族/种族,性别/性别和粉样β (Aβ) 群体中都是可比的. 这确保了对阿尔茨海默病差异的准确解释.
科学领域:
- 神经科学和认知衰老研究
- 生物标志物发现和验证
- 健康差距与公平的平等
背景情况:
- 阿尔茨海默病 (AD) 在种族/民族和性别/性别群体之间存在差异.
- 神经心理学评估对于理解认知变化和差异至关重要.
- 确保跨不同人群的认知措施的可比性对于准确解释AD差异至关重要.
研究的目的:
- 评估临床前阿尔茨海默氏症认知复合 (PACC) 和认知功能指数的测量不变性.
- 评估这些认知措施在种族/种族,性别/性别和β-粉样蛋白 (Aβ) 状态群体中的等价性.
主要方法:
- 从无症状AD (A4) 研究中的抗粉样蛋白查数据的横截面分析.
- 参与者 (65-85岁) 完成了PACC和认知功能指数.
- 在认知上正常的参与者中,通过正子发射断层扫描 (PET) 扫描确定β-粉样蛋白 (Aβ) 状态.
主要成果:
- 该研究分析了来自不同种族/族群 (非西班牙裔白人,非西班牙裔黑人,亚洲裔,西班牙裔白人) 和性别/性别 (男性,女性) 的数据.
- 对于PACC和认知功能指数的单因素模型显示,在整个样本和分层子组中都有支持.
- 在种族/种族,性别/性别和Aβ状态组中,PACC和认知功能指数均被证明具有标尺测量不变性.
结论:
- 在PACC和认知功能指数上的表现可以在所检查的种族/种族,性别/性别和Aβ状态组中可靠地进行比较.
- 这些发现支持在不同人群中使用PACC和认知功能指数进行阿尔茨海默病研究和临床评估.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
